MedTrace Logo

Prevention Trial of Family Focused Treatment in Youth at Risk for Psychosis

NCT01907282 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2013-07-24

No results posted yet for this study

Summary

Preventing psychotic disorders such as schizophrenia and associated functional disability could relieve an enormous burden of personal and family suffering and economic losses to society. This project aims to conduct a pilot randomized trial to determine the efficacy of a family-focused treatment in comparison with treatment-as-usual in enhancing functional outcomes, stabilizing symptoms, and preventing or delaying the onset of full psychosis in transitional age youth with prodromal symptoms. The results of this study will be crucial for the development of cost-effective, evidence-based psychosocial approaches to psychosis prevention and thus will have major implications for public health.

Conditions

Interventions

BEHAVIORAL

Family Focused Treatment

Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving

BEHAVIORAL

Enhanced Care

This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.

Sponsors & Collaborators

Principal Investigators

  • David J Miklowitz, PhD · UCLA Semel Institute

  • Tyrone Cannon, Ph.D. · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
FACTORIAL

Eligibility

Min Age
12 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01907282 on ClinicalTrials.gov